Cheminformatics and Structural Biology Analysis for Drug Discovery
Analyze compounds, fingerprints, scaffolds, ADMET-style properties, molecular similarity, protein structures, contacts, B-factors, SASA, and sequence or structure evidence.
Decision questions
What this solution is built to answer.
How similar are these compounds, scaffolds, or activity profiles?
What do ADMET-style properties or fingerprints suggest about a compound set?
What does a structure reveal about contacts, exposure, secondary structure, or flexibility?
Can molecular evidence feed target, indication, or competitive decisions?
Science and method
What can change the model or gate.
RDKit cheminformatics for descriptors, fingerprints, scaffold analysis, similarity, MMP-style workflows, and ADMET-style screens.
ChEMBL and PubChem access paths for compound and activity context.
Biopython, biotite, ProDy, and py3Dmol for sequence and structure work.
Structural scripts for PDB info, contact maps, Ramachandran, B-factor, SASA, secondary structure, and superposition.
Pathway and enrichment workflows with GSEA, GO, KEGG/UniProt-style service access.
Method and decision gates
How the case is computed and reviewed.
| Workflow | Role | Artifacts |
|---|---|---|
| cheminformatics | Compound and similarity analysis | Scaffold, property, fingerprint, diversity, MMP, ADMET-style outputs |
| structural-biology | Protein structure analysis | Contact maps, B-factor, SASA, secondary structure, superposition outputs |
| sequence-analysis / pathway-enrichment | Biological sequence and pathway interpretation | Alignment, enrichment, and pathway outputs |
Evidence inputs
Supporting evidence, rights and decision inputs.
Decision record
What remains available for review.
Deliverables
Compound property and similarity tables.
Scaffold, fingerprint, diversity, and ADMET-style reports.
Protein structure visualizations and metrics.
Scientific evidence files for downstream strategy or diligence.
Proof points
The analysis environment includes RDKit, Biopython, PubChemPy, ChEMBL client, pathway tools, structure tools, and py3Dmol.
Structural-biology scripts are curated rather than invented per run.
Outputs can be combined with literature, trial, patent, and valuation lanes.
Limits and review conditions
What this result does not establish.
Computed descriptors and structural analyses support expert review; they do not replace experimental confirmation.
FAQ
Common evaluation questions.
Is this only for small molecule work?
Compound workflows are one part of the surface. Structural, sequence, pathway, and network analysis workflows also cover protein and biological evidence questions.
Can scientific outputs feed valuation or strategy?
Yes. Scientific evidence can feed probability assumptions, indication scoring, competitive differentiation, diligence caveats, and board-level recommendations.
Related solutions
Biomedical Data Analysis
Analyze biomedical files, tables, model outputs, and database extracts with Python, SQL, statistics, machine learning workflows, and durable artifacts.
Indication Expansion
Scan, assess, and sequence indication opportunities with scientific rationale, clinical feasibility, competitive density, IP context, market structure, and valuation logic.
Systematic Review
Run PRISMA-style biomedical literature reviews with PubMed and PMC search lanes, screening logic, evidence tables, certainty summaries, and durable review artifacts.
Related reading
Combine scientific data and code without erasing provenance
Acquisition, normalization and computation need separate records inside the same decision case.
What a decision system must prove inside pharma
Enterprise usefulness depends on method, review and continuity across scientific and business functions.
Design scientific decision systems around methods, not prompts
Stable calculators, evidence contracts and explicit gates should carry repeatable parts of the work.